Literature DB >> 28770387

Data to Decisions: Creating a Culture of Model-Driven Drug Discovery.

Frank K Brown1, Farida Kopti2, Charlie Zhenyu Chang3, Scott A Johnson4, Meir Glick4, Chris L Waller5.   

Abstract

Merck & Co., Inc., Kenilworth, NJ, USA, is undergoing a transformation in the way that it prosecutes R&D programs. Through the adoption of a "model-driven" culture, enhanced R&D productivity is anticipated, both in the form of decreased attrition at each stage of the process and by providing a rational framework for understanding and learning from the data generated along the way. This new approach focuses on the concept of a "Design Cycle" that makes use of all the data possible, internally and externally, to drive decision-making. These data can take the form of bioactivity, 3D structures, genomics, pathway, PK/PD, safety data, etc. Synthesis of high-quality data into models utilizing both well-established and cutting-edge methods has been shown to yield high confidence predictions to prioritize decision-making and efficiently reposition resources within R&D. The goal is to design an adaptive research operating plan that uses both modeled data and experiments, rather than just testing, to drive project decision-making. To support this emerging culture, an ambitious information management (IT) program has been initiated to implement a harmonized platform to facilitate the construction of cross-domain workflows to enable data-driven decision-making and the construction and validation of predictive models. These goals are achieved through depositing model-ready data, agile persona-driven access to data, a unified cross-domain predictive model lifecycle management platform, and support for flexible scientist-developed workflows that simplify data manipulation and consume model services. The end-to-end nature of the platform, in turn, not only supports but also drives the culture change by enabling scientists to apply predictive sciences throughout their work and over the lifetime of a project. This shift in mindset for both scientists and IT was driven by an early impactful demonstration of the potential benefits of the platform, in which expert-level early discovery predictive models were made available from familiar desktop tools, such as ChemDraw. This was built using a workflow-driven service-oriented architecture (SOA) on top of the rigorous registration of all underlying model entities.

Entities:  

Keywords:  QSAR; cheminformatics; computational chemistry; information technology

Mesh:

Year:  2017        PMID: 28770387     DOI: 10.1208/s12248-017-0124-2

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  5 in total

1.  eCounterscreening: using QSAR predictions to prioritize testing for off-target activities and setting the balance between benefit and risk.

Authors:  Robert P Sheridan; Daniel R McMasters; Johannes H Voigt; Mary Jo Wildey
Journal:  J Chem Inf Model       Date:  2015-01-20       Impact factor: 4.956

2.  The evolution of drug design at Merck Research Laboratories.

Authors:  Frank K Brown; Edward C Sherer; Scott A Johnson; M Katharine Holloway; Bradley S Sherborne
Journal:  J Comput Aided Mol Des       Date:  2016-11-23       Impact factor: 3.686

3.  Lead- and drug-like compounds: the rule-of-five revolution.

Authors:  Christopher A Lipinski
Journal:  Drug Discov Today Technol       Date:  2004-12

Review 4.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.

Authors:  David Cook; Dearg Brown; Robert Alexander; Ruth March; Paul Morgan; Gemma Satterthwaite; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2014-05-16       Impact factor: 84.694

Review 5.  Changing R&D models in research-based pharmaceutical companies.

Authors:  Alexander Schuhmacher; Oliver Gassmann; Markus Hinder
Journal:  J Transl Med       Date:  2016-04-27       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.